The dream of an “off-the-shelf” T-cell therapy has become a reality, courtesy of the allogeneic aficionados over at Atara Biotherapeutics. Monday, the company’s allogeneic Epstein-Barr virus-positive ...

Atara Biotherapeutics ATRA is a nimble allogeneic T cell immunotherapy company with several near-term catalysts. This Zacks Rank #2 (Buy) company boasts a pipeline of differentiated therapies across a ...

Nguyen AnhCo, the President and CEO of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), has reported the sale of 1,664 shares of common stock. The transaction, which took place on November 18, 2024, was ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

Atara Biotherapeutics continues to salami slice its head count, this time laying off 30% of what remains of the biopharma's workforce. Only three months ago, the company waved goodbye to half of its ...

The latest price target for Atara Biotherapeutics (NASDAQ:ATRA) was reported by Canaccord Genuity on March 11, 2025. The analyst firm set a price target for $17.00 expecting ATRA to rise to within 12 ...

Atara Biotherapeutics sees European approval for tab-cel, signaling potential in oncology and autoimmune diseases, despite US regulatory hurdles. Recent financials show decreased losses, reduced ...

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.96 per share a year ago. These ...

Atara Biotherapeutics Inc. (ATRA) announced Greg Ciongoli will serve as chair of the board of directors, according to a company... Director James Huang of Atara Biotherapeutics, Inc. (NASDAQ: ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop ...

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value of ...